Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.08, read 2026-10-27
Ethical passes the values gate
Price72.74 USD
Fair value63.81
Our investment reviews on this name
2026-10-28Read Accumulation66.94+8.7% to today ✓Markdown gives way to Accumulation
2026-10-21Read Markdown66.94+8.7% to today Accumulation gives way to Markdown
2026-08-26Read Accumulation67.64+7.5% to today ✓Markup gives way to Accumulation after a 26% rise in 8 weeks
2026-07-02Read Markup53.64+35.6% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Nutanix, Inc. holds its Accumulation at $72.74. Consolidating, no directional conviction, held for 81 days.
As held on the ledger · 2026-10-27
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 81 days
Price at the screen
$72.74
Valuation
12.95 trailing · 25.05 forward price to earnings
Values screen
PASS
Beta
0.64
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
12.31%
Below 33%
Interest-bearing debt is just 12.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
14.91%
Below 33%
Cash held in interest-bearing accounts and securities is 14.9% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
2.69%
Below 5%
Only 2.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Nutanix, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 12%, inside the ~33% line, and interest is about 3% of its income, under the ~5% line, so it passes.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when NTNX's ethical verdict changes
Today NTNX passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. The price runs 4.7% above the base estimate.
Third-party analyst targets: 14 covering, consensus Buy. The average target sits +5% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Nutanix chases cloud growth without a moat
Picture a mid-sized firm swapping its old servers for a slick cloud setup. Nutanix sells the software that makes that switch feel simple. Yet the business shows little edge over bigger rivals, and the numbers do not scream opportunity.
Revenue is rising just 10 percent a year with profit margins stuck at 10 percent. The shares trade at 25 times forward earnings, only 6 percent below our fair value. A weak moat and middling growth leave little room for error at current prices.
Analysts still favour the name, but fierce competition can quickly cap pricing power and margins. Ethical checks clear, yet the financial profile does not.
Analysis, not advice.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NTNX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 36% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. Since the last review it dropped out of the Tech 100.
2026-10-21Markdown · changed$66.94-10.3%Entry 15
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.3% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55.
2026-10-14Accumulation$74.63+6.5%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.5% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55.
2026-10-02Accumulation$70.09+3.6%Entry 13
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-25Markup$67.64+0.0%Entry 11
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-24Markup$67.64+0.0%Entry 10
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-23Markup$67.64+0.0%Entry 9
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-22Markup$67.64+12.5%Entry 8
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.5% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-21Markup$60.12+0.0%Entry 7
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 34%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (15 analysts) rates it buy, with a mean price target of $55. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
